Advanced Certificate in Antiviral Drug Development for Physicians
-- ViewingNowThe Advanced Certificate in Antiviral Drug Development for Physicians is a comprehensive course designed to equip medical professionals with the latest knowledge and skills in antiviral drug development. This certificate course highlights the importance of antiviral drugs in the current medical landscape and the growing demand for experts in this field due to the ongoing battle against viral diseases and the recent COVID-19 pandemic.
7,083+
Students enrolled
GBP £ 140
GBP £ 202
Save 44% with our special offer
ๅ ณไบ่ฟ้จ่ฏพ็จ
100%ๅจ็บฟ
้ๆถ้ๅฐๅญฆไน
ๅฏๅไบซ็่ฏไนฆ
ๆทปๅ ๅฐๆจ็LinkedInไธชไบบ่ตๆ
2ไธชๆๅฎๆ
ๆฏๅจ2-3ๅฐๆถ
้ๆถๅผๅง
ๆ ็ญๅพ ๆ
่ฏพ็จ่ฏฆๆ
Here are the essential units for an Advanced Certificate in Antiviral Drug Development for Physicians:
• Overview of Antiviral Drug Development: This unit covers the basics of antiviral drug development, including the drug development process, regulatory requirements, and the role of physicians in antiviral drug development.
• Antiviral Drug Targets: This unit explores the various targets for antiviral drugs, including viral enzymes, viral entry into cells, and viral replication. It also covers the latest research in antiviral drug targets.
• Antiviral Drug Design and Discovery: This unit covers the latest techniques and tools used in antiviral drug design and discovery, including high-throughput screening, structure-based design, and computational chemistry.
• Preclinical Development of Antiviral Drugs: This unit covers the preclinical development of antiviral drugs, including in vitro and in vivo testing, pharmacokinetics, and toxicology.
• Clinical Trials of Antiviral Drugs: This unit explores the various stages of clinical trials for antiviral drugs, including phase I, II, and III trials. It also covers the ethical considerations and regulatory requirements for clinical trials.
• Approval and Post-Marketing Surveillance of Antiviral Drugs: This unit covers the process of approval for antiviral drugs by regulatory agencies such as the FDA, as well as post-marketing surveillance and pharmacovigilance.
• Emerging Viruses and Antiviral Drug Development: This unit explores the challenges and opportunities of developing antiviral drugs for emerging viruses, including COVID-19, Ebola, and Zika virus.
• Antiviral Drug Resistance and Management: This unit covers the issue of antiviral drug resistance, including the mechanisms of resistance, the
่ไธ้่ทฏ
ๅ ฅๅญฆ่ฆๆฑ
- ๅฏนไธป้ข็ๅบๆฌ็่งฃ
- ่ฑ่ฏญ่ฏญ่จ่ฝๅ
- ่ฎก็ฎๆบๅไบ่็ฝ่ฎฟ้ฎ
- ๅบๆฌ่ฎก็ฎๆบๆ่ฝ
- ๅฎๆ่ฏพ็จ็ๅฅ็ฎ็ฒพ็ฅ
ๆ ้ไบๅ ็ๆญฃๅผ่ตๆ ผใ่ฏพ็จ่ฎพ่ฎกๆณจ้ๅฏ่ฎฟ้ฎๆงใ
่ฏพ็จ็ถๆ
ๆฌ่ฏพ็จไธบ่ไธๅๅฑๆไพๅฎ็จ็็ฅ่ฏๅๆ่ฝใๅฎๆฏ๏ผ
- ๆช็ป่ฎคๅฏๆบๆ่ฎค่ฏ
- ๆช็ปๆๆๆบๆ็็ฎก
- ๅฏนๆญฃๅผ่ตๆ ผ็่กฅๅ
ๆๅๅฎๆ่ฏพ็จๅ๏ผๆจๅฐ่ทๅพ็ปไธ่ฏไนฆใ
ไธบไปไนไบบไปฌ้ๆฉๆไปฌไฝไธบ่ไธๅๅฑ
ๆญฃๅจๅ ่ฝฝ่ฏ่ฎบ...
ๅธธ่ง้ฎ้ข
่ฏพ็จ่ดน็จ
- ๆฏๅจ3-4ๅฐๆถ
- ๆๅ่ฏไนฆไบคไป
- ๅผๆพๆณจๅ - ้ๆถๅผๅง
- ๆฏๅจ2-3ๅฐๆถ
- ๅธธ่ง่ฏไนฆไบคไป
- ๅผๆพๆณจๅ - ้ๆถๅผๅง
- ๅฎๆด่ฏพ็จ่ฎฟ้ฎ
- ๆฐๅญ่ฏไนฆ
- ่ฏพ็จๆๆ
่ทๅ่ฏพ็จไฟกๆฏ
่ทๅพ่ไธ่ฏไนฆ
